Intranasal Dexmedetomidine Sedation in Children for Non-painful Procedures
Launched by COLUMBIA UNIVERSITY · Jul 14, 2017
Trial Information
Current as of June 07, 2025
Completed
Keywords
ClinConnect Summary
Dexmedetomidine (DEX) is an alpha-2 receptor agonist with sedative, anxiolytic, and analgesics properties. DEX has been used extensively for sedation in children to facilitate different non-painful procedures, such magnetic resonance imaging (MRI), auditory brainstem response (ABR) tests, and computed tomography (CT) scans. In particular, DEX can be administered by the intranasal (IN) route. Intranasal administration has the benefits of being both effective and needle-free, of which the latter makes it less distressing to children compared to sedatives administered by the intravenous (IV) r...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Children 2 months to 17 years (i.e. before their 18th birthday)
- • Child will be receiving intranasal dexmedetomidine as part of their usual medical care
- • Child will be undergoing a non-painful medical procedure, which includes (but is not limited to): MRI, CT scans, ABR/BAER, echocardiograms, and EEGs.
- Exclusion Criteria:
- • Known allergy to dexmedetomidine
- • Known abnormal renal or hepatic function
- • Known cardiac conduction abnormality or heart block
- • Current use of digoxin or beta-blockers
About Columbia University
Columbia University, a prestigious Ivy League institution located in New York City, is a leading sponsor of clinical trials dedicated to advancing medical research and improving patient care. With a robust network of research facilities and a commitment to innovation, Columbia University collaborates with a diverse range of healthcare professionals and researchers to explore groundbreaking therapies and treatment methodologies. The university's clinical trials encompass various fields, including oncology, neurology, and public health, aiming to translate scientific discoveries into effective clinical applications. Columbia University is dedicated to maintaining the highest ethical standards and regulatory compliance, ensuring the safety and well-being of trial participants while contributing to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cincinnati, Ohio, United States
Houston, Texas, United States
Pittsburgh, Pennsylvania, United States
San Jose, California, United States
Boston, Massachusetts, United States
Atlanta, Georgia, United States
Springfield, Illinois, United States
Chapel Hill, North Carolina, United States
Patients applied
Trial Officials
Daniel S Tsze, MD, MPH
Principal Investigator
Columbia University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials